Anacor Scores $100M In Valeant Fungus Drug Feud

Law360, Chicago (October 21, 2013, 1:23 PM EDT) -- Valeant Pharmaceuticals International Inc. has been ordered to cough up $100 million to Anacor Pharmaceuticals Inc. in arbitration over a contract dispute concerning Valeant's developmental nail fungus treatment, the companies said Friday.

As a result of an arbitration hearing held last month, Canada-based Valeant must make a one-time payment of $100 million in damages plus costs and fees to Anacor, but the arbitrator did not impose an injunction or ongoing royalty that would hinder the launch of the drug known as Jublia, Valeant said in a...
To view the full article, register now.